UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM. 10-QSB

[ X ] QUARTERLY REPORTS UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2001.

[ ] QUARTERLY REPORTS UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ______________.

Commission File No. 0-19844

-----------

PARACELSIAN, INC.

------------------------------------------------------

(Exact name of small business issuer as specified in its charter)

Delaware		16-1399565
-----------		-----------------
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
222 Langmuir Laboratories, Cornell Technology Park, Ithaca, New York		14850
------------------------------------------------------------------		-------------------
(Address of principal executive offices)		Zip Code

Issuer's telephone number: (607) 257-4224 -----------------------------------------------------

Check whether the issuer (1) filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports, and (2) has been subject to such filing requirements for the past 90 days.

Yes [ X ] No [ ]

There were 23,526,849 shares of Common Stock outstanding at May 1, 2001

(PAGE 1)

Paracelsian, Inc. and Subsidiary

Index

Page

PART I. — FINANCIAL INFORMATION

Item 1. Financial Statements

Consolidated Balance Sheet as of March 31, 2001 (Unaudited)

Consolidated Statements of Operations for the three months and six months ended March 31, 2001 and 2000 and the cumulative period from inception to March 31, 2001 (Unaudited)

Consolidated Statements of Cash Flows for the six months ended March 31, 2001 and 2000 and the cumulative period from inception to March 31, 2001 (Unaudited)

Notes to Consolidated Financial Statements (Unaudited)

Item. 2 — Management’s Discussion and Analysis of Financial Condition and Results of Operations

PART II — OTHER INFORMATION

Item 1 — Legal Proceedings

Item 6 — Exhibits and Reports of Form 8-K

Signatures

(PAGE 2)

Paracelsian, Inc. and Subsidiary
(A Development Stage Company)
Consolidated Balance Sheet
March 31, 2001 (Unaudited)

		March 31, 2001
	Assets
Current Assets:
	Cash and cash equivalents	$4,746
	Inventory	-
	Prepaid expenses	59,382
	Other current assets	30,445
	Total current assets	94,573

Equipment, net		108,484
Interest Receivable		45,988
Note Receivable		148,750
Other Assets:
	TCM extracts on-hand	-
	Patents and trademarks, net	204,845
		508,067
		$602,640
	Liabilities and Stockholders’ Equity (Deficit)
Current Liabilities:
	Accounts payable	$466,032
	Accrued expenses	566,312
	Current portion of capital lease obligation	1,975
	Current portion of notes payable	139,206
	Advances from related party	191,877

	Total current liabilities	1,365,402
Long-term Liabilities:
	Long-term portion of capital lease obligation	6,084
	Long-term portion of notes payable	12,150
	Total current and long-term liabilities	1,383,636

Stockholders’ Equity (Deficit)
	Common Stock, $.01 par value; 35,000,000 shares authorized;
	23,520,849 shares outstanding	234,904

	Additional paid-in-capital	25,404,381
	Deficit accumulated during the development stage	(25,077,766)
	Treasury stock, at cost; 265,478	(1,342,515)
	Total stockholders’ equity (deficit)	(780,996)
		$602,640

See accompanying notes to consolidated financial statements

(PAGE 3)

Paracelsian, Inc. and Subsidiary (A Development Stage Company) Consolidated Statements of Operations For the three months and six months ended March 31, 2001 and 2000, And the cumulative period from inception to March 31, 2000 (Unaudited)

		Three Months Ended March 31,		Six Months Ended March 31,		Cumulative Period from Inception to March 31,
		2001	2000	2001	2000	2001
Revenues:

	Marketing rights	59,866	65,969	123,121	116,358	974,793
	Products	2,964	-	7,162	1,138	259,180
	Product testing	5,614	25,372	5,614	50,892	167,991
	Development fees	-	-	-	-	1,246
	Product royalties	-	-	-	-	31,625
	Subscription revenue	-	-	-	-	-

	Total Revenues	68,444	91,341	135,897	168,388	1,434,835

Operating expenses:
	Research and product engineering	132,751	150,783	255,696	304,786	9,437,727
	General and administrative	214,242	277,755	471,888	576,337	14,939,055
	Product launch costs	-	-	-	-	300,544
	Cost of products sold	357	-	1,752	-	268,464

	Total Operating expenses	347,350	428,538	729,336	881,123	24,945,790

	Loss from operations during the development stage	(278,906)	(337,197)	(593,439)	(712,735)	(23,510,955)

Interest income (expenses), net		20,465	-	20,279	16,312	522,701

Gain on sale of assets		-	-	-	-	38,488

	Net loss during the development stage	(258,441)	(337,197)	(573,160)	(696,423)	(22,949,766)

	Basic and diluted net loss per share of common stock	(0.01)	(0.02)	(0.02)	(0.03)

	Weighted average number of Common Shares outstanding	23,492,182	20,761,748	23,491,508	20,716,647


See accompanying notes to consolidated financial statements.

(PAGE 4)

Paracelsian, Inc. and Subsidiary

(A Development Stage Company)
Consolidated Statements of Cash Flows
For the six months ended March 31, 2001 and 2000,
And the cumulative period from inception to December 31, 2001
(Unaudited)

			Cumulative
			Period from
	Six Months Ended		Inception to
	March 31,		March 31,
Cash flows from operating activities:	2001	2000	2001

Net loss	$(573,160)	(696,423)	(22,949,766)
Adjustments to reconcile net loss to net cash used in
operating activities:
Gain on the sale of assets	-	-	(6,968)
Non-cash compensation expense	-	-	1,475,301
Other non-cash expenses	-	-	2,071,985
Depreciation and amortization	41,446	114,460	2,388,791
Changes in assets and liabilities:
Interest receivable	(19,135)	-	(45,988)
Inventories	926	-	-
Prepaid expenses and other current assets	(46,528)	17,349	(89,827)
Accounts payable	103,782	143,420	466,032
Deferred revenue	-	(57,000)	-
Accrued expenses	168,569	(89,257)	566,312

Net cash used in operating activities:	(324,100)	(567,451)	(16,124,128)

Cash flows from investing activities:
Purchase of equipment	(3,805)	-	(741,671)
Proceeds from sale of equipment	-	-	26,968
Acquisition of licensed technology	-	-	(53,656)
Acquisition of patents and trademarks	(3,547)	-	(496,719)
Acquisition of New Century Nutrition newsletter	-	-	(350,000)
Acquisition of option for East West Herbs, Ltd. and related acquisition costs	-	-	(92,866)
Loan to East West Herbs, Ltd.	-	-	(340,000)
Proceeds from loan to East West Herbs, Ltd.	-	-	42,500

Net cash used in investing activities	(7,352)	-	(2,005,444)

Cash flows from financing activities:
Sale of common stock, initial public offering, net of costs	-	-	5,124,014
Sale of common and preferred stock, net of costs	-	-	11,776,088
Proceeds from the sale of common stock	-	-	500,000
Proceeds from the exercise of warrants	-	-	1,219,640
Proceeds from the exercise of options	-	-	68,900
Termination of warrants	-	-	-
Purchase of treasury stock	-	-	(1,342,515)
Cost of warrant dividend	-	-	(63,102)
Increase in capital lease obligations and notes payable	-	-	115,868
Payment on capital lease obligations		(5,782)	(22,663)
Proceeds from advances from related party	-	-	797,350
Payments on advances from related party	-	-	(105,473)
(Decrease) increase in notes payable	109,075	541,491	66,211

Net cash provided by financing activities	109,075	535,709	18,134,318

Net increase (decrease) in cash and cash equivalents	(222,377)	(31,742)	4,746
Cash and cash equivalents, beginning of period	227,123	72,754	-

Cash and cash equivalents, end of period	$4,746	41,012	4,746

Supplemental disclosures:
Cash paid during the period for interest	$16,086	3,421	97,400

Supplemental disclosure of non-cash investing & financing activities:
Fair value of assets acquired, net of cash acquired	$-	-	1,733,212
Less - liabilities assumed	-	-	83,212
Less - issuance of common stock	-	-	1,644,000

Net cash paid			6,000

Warrant dividend	-	-	500,000
Issuance of common stock/warrants for services and to reduce liabilities	-	-	1,455,432
Purchase of equipment	-	-	90,950
Purchase of officer stock subscription receivable	-	-	89,850
Issuance of common stock for licensing and technology rights	$-	-	3,338

See accompanying notes to consolidated financial statements.

(PAGE 5)

Paracelsian, Inc. and Subsidiary

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2001

(Unaudited)

1. BASIS OF PRESENTATION:

The consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles without audit, pursuant to the rules and regulations of the Securities and Exchange Commission applicable to quarterly reporting on Form 10-QSB and reflect, in the opinion of the Company, all adjustments necessary to present fairly the financial position and results of operations for Paracelsian, Inc. and its consolidated subsidiary. All such adjustments are of a normal and recurring nature. Certain information and footnote disclosures normally included in financial statements, prepared in accordance with generally accepted accounting principles, have been condensed or omitted as permitted by such regulations. These consolidated financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-KSB for the fiscal year ended September 30, 2000.

The SAS # 71 review has not been completed prior to the filing of the Form 10-QSB for the quarterly period ended March 31, 2001.

2. ORGANIZATION, BUSINESS, AND RISK FACTORS:

Organization and Business

Paracelsian is a development stage company, which develops and applies bioassays to monitor environmental toxins, to determine the quality of herbal products, and to identify therapeutic compounds from herbal sources (www.paracelsian.com).

The Company has developed a highly sensitive, user friendly, cost effective testing system for the detection and quantification of highly toxic environmental chemicals generally known as dioxin and dioxin-like compounds. It is called the Ah-IMMUNOASSAY® Kit (AH-1 Method).

Since the discovery of the dioxin compounds, during the late 1950’s, extensive research has been undertaken into their chemical and biological properties. And as more information becomes available, it is now clear that the original and narrowly defined group of ‘dioxins’ is becoming more expansive to include many other highly toxic, chemically similar compounds.

Dioxin, although singular in name, is actually comprised of at least 17 chemical variants or congeners of a larger dioxin family. These chemicals are highly toxic, with the most active congener (TCDD) being the most toxic chemical ever discovered. The number of chemicals with dioxin-like activity is even much larger still than the 17 original polychlorodibenzo-p-dioxin (PCDD) families, such as the polychlorodibenzofurans (PCDF), the polychlorinated biphenyls (PCBs), the polybrominated biphenyls (PBBs), the polycyclic aromatic hydrocarbons (PAHs), the heterocyclic amines (HAs), among others.

Probably no other group of chemicals has invoked more public health concern and received more media attention than these dioxin and dioxin-like substances, both because of their widespread distribution and their capability for serious toxicity (e.g., cancer, birth defects, diabetes, hormone disruption, immunologic dysfunction, etc.). The Environmental Protection Agency (EPA) of the United States has concluded, for example, that more than 100 of these dioxins and dioxin-like chemicals are likely human carcinogens.

Waste incineration is a major source of these chemicals. Paper mill bleaching and varied industrial syntheses also add significant amounts to the environment. Following release into the air, perhaps also into waste water or sludge, these chemicals then settle on plant material, soil, and water where they are likely to persist for very long periods of time. As a consequence, they tend to accumulate either onto particulate matter (such as found at the bottom of bodies of water), or into body fat reservoirs of animals and fishes which feed on the plants. And because of their stability and persistence, these chemicals accumulate to relatively high levels in animal based foods.

Investigating the distribution and toxicities of these chemicals has been challenging, both because of the ever-growing number of chemicals with dioxin-like activity and the difficulty of predicting toxicities. Because of these complexities, analysis of these chemicals has been very expensive, with the results being difficult to interpret.

More recently, simpler analytical methods have been developed, such as the AH-1 Method, based on the use of biologically based concepts. Dioxins and dioxin-like chemicals (also called ligands), enter the cell and bind to a protein in the cytoplasm called Ah receptor (AhR), thus giving a ligand-AhR complex. This complex, by dropping and adding some smaller proteins (e.g., AhR translocator or ARNT, hsp-90 protein) is said to be ‘transformed’, thus enabling it to enter the nucleus to bind to a specific ‘dioxin receptor element’ (or enhancer) (DRE) of DNA. This interaction with DNA occurs ‘upstream’ of genes which then are activated to produce certain enzymes, some of which are highly correlated with the subsequent toxicity.

The AH-I Method takes advantage of these facts. It is generally acknowledged, for example, that AhR binding appears to be essential for the development of toxicity by these chemicals. It is as if ligand binding of AhR is the main traffic intersection through which these chemicals pass on their way to produce their respective toxicities.

In the AH-I Method, where an excess of AhR protein is provided, the amount of AhR-ligand complex that transforms is dependent on the amount of dioxin ligand present in the sample being assayed. The amount of the transformed complex is detected by using an antibody specific for the Ah-I protein component of the complex, thus giving the ‘Immunoassay’ name to the method. (For the scientifically minded reader, there really are two antibodies: the first interacts with the ARNT protein in the complex while the second, containing an enzyme that catalyzes the formation of the color reaction, binds to the first antibody. The color being produced in the reaction shows how much of the complex is present.).

Dioxin is a toxic chemical group of widespread public health concern, and more information is needed, especially on the distribution of this material in the environment. More survey data are needed not only to identify potential ‘hot spots’ but also to allay unwarranted concerns. Until now, such survey work has been prohibitively expensive, but with the introduction of simpler and much more cost effective bioassay methods, such as the AH-1 Method, it is now possible to gather far more information in order to make wiser decisions.

The herbal supplement market presents the opportunity to commercialize a quality assurance program that identifies the bioactivity present in herbal products, which are complex mixtures of substances. This product is a significant advance versus current practices for verifying the quality and the bioactivity of herbal products. This is the Company’s BioFIT™ Quality Assurance Certification Program.

Typically, the Company will investigate the effect of a compound or mixture of compounds on a disease (such as cancer) or a symptom (such as depression). The Company scientists conduct in depth research of the scientific literature and review the results of successful clinical trials to establish the best scientific explanation for the positive results seen in such trials. Based on their review, they identify the biological mechanism which, if activated, would best explain the positive clinical results. By defining such mechanisms of action associated with a wide variety of biological effects the Company scientists can then test a wide variety of natural materials in "in vitro" models which demonstrate these effects for the purpose of either discovering or confirming these biological activities. Such discovery or confirmation provides the Company with the basis for its BioFIT™ Program.

The Company is continuing to work with its Chinese colleagues, during the appropriate market conditions, to expand the scope of the BioFIT™ program to the rest of the world.

The Company is engaged in an internet-based health exchange between the US and China and currently maintains the website www.newcenturynutrition.com. The Company has excellent relations with recognized health authorities and organizations within the People’s Republic of China. This website serves to provide a forum for the exchange of nutrition, health and related information. At its core is the New Century Nutrition website where renowned researchers, teachers and physicians from both countries can discuss their philosophies, research findings and health advice. Other components of the site include an herbal resource center featuring herbal databases from China, a nutrition resource center featuring healthy recipes and a technology center featuring the Ah-IMMUNOASSAY® Kit and the BioFIT™ Program. Our goal is to combine the best of Chinese medical practice with the best of Western practice creating new opportunities for information on health and disease prevention.

Development Stage Company and Risk Factors

The Company is considered to be a development stage company as defined in Statement of Financial Accounting Standards No. 7, "Accounting and Reporting by Development Stage Enterprises." Since inception, the Company has been primarily engaged in research, product engineering and raising capital.

The Company, as a development stage enterprise, has yet to generate significant revenues and has no assurance of substantial future revenues. The Company is subject to a number of risks that may affect its ability to become an operating enterprise or impact its ability to remain in existence, including risks related to successful development and marketing of its products, patent protection of proprietary technology, government regulation, competition from substitute products (including technologies that may not yet have been developed), dependence on key employees and the need to obtain additional funds that may not be available to it.

As shown in the accompanying financial statements, the Company incurred a net loss of approximately $573,000 for the six months ended March 31, 2001 and had a working capital deficit of approximately $1,270,000 at March 31, 2001. Operating expenses decreased by $152,000 (17%) as a result of decreases in a variety of expense categories, as part of the company's program to control costs. Management believes that revenues from the sale of Ah-IMMUNOASSAY® Kits will accelerate throughout the coming year, and coupled with a continual program to control costs, the Company will achieve positive cash flow from operations during 2001. Until such revenues are realized on a sustained basis, the Company will require additional capital to meet its obligations and continue operations.

(PAGE 7)

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Six months ended March 31, 2001 as compared to the

Six months ended March 31, 2000

As a development stage enterprise, the Company, since inception, has been primarily engaged in research, product engineering, and capital formation. As such, the Company has not generated significant revenues to date on a recurring basis.

The Company signed a final Licensing Agreement on January 21, 2000 with Kubota Corporation for the sale of Paracelsian’s Ah-IMMUNOASSAY® in the Japanese market and began manufacturing and selling kits to Kubota. This 'bioassay' based kit is rugged, user-friendly, portable, analytically sensitive, and low cost when compared with existing methodology. The agreement with Kubota will provide revenues from the sale of kits and royalties.

On June 15, 2000 the Company announced that in accordance with the License Agreement, Kubota agreed to pay the $150,000 License Fee. This payment signifies Kubota's acceptance of the Ah-IMMUNOASSAY® Kit. Kubota and Paracelsian will now focus their efforts to market, sell and distribute the kit throughout Japan. On June 17, 2000 Kubota placed an initial order for 120 Ah-IMMUNOASSAY® Kits, and have placed monthly orders since June 2000.

On November 2, 2000 the Environmental Protection Agency (EPA) held an open meeting for public comment on the Dioxin Reassessment Report. Approximately 50 people from around the US were scheduled to present their comments to the Science Advisory Board Dioxin Reassessment Review Committee. Dr. T. Colin Campbell, President & CEO of Paracelsian, reported to the committee his concerns about including in the report all of the dioxin and dioxin-like chemicals because of their capability for serious toxicity. On May 18, 2001 the EPA announced that the report will be sent to EPA Administrator Christie Whitman. The report concluded that chlorinated dioxin is an air pollutant that should be more tightly controlled. The findings could provide the basis for federal regulators to impose limits on dioxin that go beyond current voluntary controls.

The Ah-IMMUNOASSAY® Kits are continuing to be sold to the Kubota Corporation for the sale and distribution of the Ah-IMMUNOASSAY® in Japan. Kits have also been sold to Cypress Diagnostics in Belgium for the testing of animal feed. The University of Liege in Belgium has purchased kits for animal serum and tissue screening. SGS Agrilab in Antwerp, Belgium is the world’s largest inspection organization with 340 laboratories worldwide. SGS is waiting for the University of Liege screening results, and predicts a large market in Belgium. The Danish and Veterinary and Food Administration have purchased kits for the testing of fish, milk and fat. MCS Diagnostics is testing our kit for use in the German milk program. Dynex Technologies is using the kit for animal feed, food and environmental samples in the Czech and Slovak Republics. KNJ Engineering is using the kit with one of their customers, LG Chemical of Korea. KNJ sells dioxin-sampling equipment to incinerators and other applications in Korea. The Company has also begun discussions with Marubeni for exclusive distribution in Korea. Solutia has purchased the kit for testing organic material, and Scientific Supply Company purchased the kit for soil, milk powder and feed samples. Sales have also been made to Bristol Myers Squibb and Lockheed Martin.

Additionally, the Company has a note receivable outstanding, including accrued interest, with a balance outstanding of $370,000. The Company is continuing its efforts to collect the entire amount of this receivable. The Company also has an inventory of Andrographis paniculata that it is attempting to sell through its Internet sites (www.newcenturynutrition.com and www.paracelsian.com/). Andrographis is an annual plant that grows in much of Asia. Modern research has examined the effect of Andrographis on various viral infections and general immunological functions, and the research has indicated very promising results. Because this inventory has been slow moving, the Company has written it off completely. However, the Company will continue with its efforts to sell this inventory. If it is successful in its efforts, the retail value could approximate $400,000.

The Company’s plan is to continue to advance the Ah-IMMUNOASSAY® technology so as to be the premier screening and monitoring methodology within the worldwide marketplace. To fund certain of its continual development expenses the Company, in January 2001, received an initial approval for a grant from the New York State Energy Research and Development Authority which could result in funding up to $180,000 (unaudited).

Management is also aggressively seeking an investment of at least $1,000,000 to strengthen its working capital position, and active discussions with a number of interested parties are continuing. Current monthly cash requirements in order to sustain meaningful operations are approximately $65,000 and management fully expects to meet its financial obligations as described above.

The actions described above represent the Company’s plans to generate cash flow, thereby enabling the Company to continue to operate as a going concern. There is no assurance that these efforts will be successful.

Results of Operations

The Company’s net loss for the second quarter of fiscal 2001 was approximately $258,000 compared to $337,000 in the second quarter of fiscal 2000. Revenues for the three-month period were $68,000 in 2001 as compared to $91,000 in 2000. Operating expenses for the three-month period were approximately $347,000 compared to $429,000 for the first fiscal quarter of the prior year. The decrease of $82,000 (19%) is due to a decrease in a number of expense categories. The management team is continuing to operate with modest staff levels and has been focusing on continuing to optimize the use of its resources, increasing its customer base and generating revenues.

Liquidity & Capital Resources

As of March 31, 2001, the Company had cash of $4,700 and a net working capital deficit of $1,270,000. Management believes that it can continue to raise additional capital, to support its operations until such time as the revenue stream is sufficient to realize positive cash flow in 2001. Management believes that the additional financing coupled with its expected revenues from the Ah-IMMUNOASSAY®, the collection of the outstanding note receivable and the sale of its inventory of Andrographolide will enable the Company to further improve its operating efficiency and to continue its operations into the future.

Management and The Board

The management of the Company will be focusing their efforts on bringing the Company products and services to market in a timely manner, producing ongoing revenues and controlling expenses.

Short Term Advances

BioSignia, Inc., the Company’s largest shareholder, has advanced interim funds to the Company for working capital purposes. The Company agreed to repay the funds, together with interest at an annual rate of 10%, at the earlier of 30 days from the date of the advance or the receipt by the Company of proceeds from the sale of stock. On June 19, 2000, the Board of Directors agreed to accept BioSignia's offer to convert $500,000 of debt into common stock of Paracelsian at $.40 per share. Through March 31, 2001, the principal portion of advances from BioSignia aggregated $191,877.

Patents

The Japanese Patent Office in March 2001 issued to the Company Patent # 3144689 for the detection of dioxin-like compounds through the use of the Paracelsian’s Ah-IMMUNOASSAY® Kit. This patent, which is equivalent to US patent # 6,127,136 is Paracelsian’s sixth patent related to the Ah-IMMUNOASSAY® Kit

Forward Looking Statements

Certain statements in this Form 10-Q "Management's Discussion and Analysis of Financial Condition and Results of Operations" constitute "forward looking statements" within the meaning of the Private Securities Litigation Reform act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such factors include, among others, the following: success of operating initiative, advertising and promotional efforts, acceptance of new product offerings, availability, changes in business strategy or development plan, availability and terms of capital, labor and employee benefit costs, and other factors specifically referred to in this 10-Q.

(PAGE 9)

PART II OTHER INFORMATION

Item 1. Legal Proceedings

Hadyk, et al. V. John G. Babish, et al.

On February 14, 2001 the Hadyk, et al. V. John G. Babish, et al. case that was commenced in the New York State Supreme Court (Onondaga County) in June 1993 by certain persons against the Company was dismissed.

This case was commenced by certain person, individually and doing business as In Vitro Bioanalytic Systems, against the Company, Dr. John G. Babish, a former officer and director of the Company, and Edward Heslop, a founding shareholder of the Company, primarily as an action for money damages and injunctive relief against the Company for alleged misappropriation of proprietary information and unfair competition. The plaintiffs alleged, among other things, that in 1990, prior to the Company’s incorporation, a partnership had been formed with Messrs. Babish and Heslop to commercialize products that the Company was developing. Damages, an accounting and an injunction were being sought against the Company. By decision dated September 14, 1994, the Court dismissed certain of the plaintiffs’ claims against the Company while permitting a claim alleging unfair competition to proceed. Discovery had been temporarily stayed pending resolution of a motion for summary judgment brought by certain of the Company’s co-defendants. That motion was successfully and fully resolved, and the Court, on February 14, 2001, ruled in favor of the Company. The Court not only exonerated the Company of any wrongdoing, but also reflected the plaintiffs’ fundamental premise that they had a property interest in the technology at issue in this case.

Item 6(a) Exhibits

None

Item 6(b) Reports on Form 8-K

None

SIGNATURES

In accordance with Section 13 or 15 (d) of the Securities and Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date May 21, 2001

PARACELSIAN, INC.

                                                                                                  By:/s/ T. COLIN CAMPBELL
                                                                                                 -------------------------------------
                                                                                                 T. Colin Campbell
                                                                                                 President,
                                                                                                 Chief Executive Officer

                                                                                                By/s/ GARY G. CHABOT
                                                                                                 ---------------------------------
                                                                                                 Gary G. Chabot
                                                                                                 Principal Accounting Officer

(PAGE 12)

PARACELSIAN INC /DE/ 10-Q